Alimera Reports Results From The Six-Month Interim Readout Of The Human PK Iluvien(TM) Study
Oct 3rd 2008Drug InformationClinical Trials
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
